PURPOSE: The aim of the study was to investigate a possible neurotransmitter role of VIP on airway smooth muscle relaxation in COPD patients. Also we compared the values of serum acsorbate concentration and serum level of VIP with lung function and laboratory tests of inflammation.
METHODS: VIP was determined by RIA kits from the laboratory of the Hammersmith Hospital in London, and serum ascorbate concentration was determined using spectrophotometric method. The serum level of VIP and C vitamin were measured in 40 non-smokers patients. Patients were divided into two groups. Group I included 20 patients with COPD in stable state and Group II: 20 patients with exacerbation of the disease. Diagnosis was established by clinical, roentgenographic, laboratory and lung function examinations. Laboratory analyses included blood leukocyte count, ESR and serum fibrinogen.
RESULTS: Spirometry in Group I patients showed: VC=2.38••0.70 l (74.45%), FEV1=1.39•0.41l (5627%) and 100•FEV1/VC=61.39•11.92 and Group II: VC=2.17•0.81 l (64.78%), FEV1=1.28•0.43 l (52.12%) and 100• FEV1/VC=57.43•14.91. Serum level of VIP was significantly higher, and serum vitamin C concentration was significantly decreased in group II patients before therapy. The patients in group I had normal serum levels of VIP and vitamin C before and after therapy.
CONCLUSION: It is conclude that our results showed significantly decreased serum vitamin C concentration and significantly higher serum levels of VIP in COPD patients during exacerbation before therapy compared to patients after therapy. The patients with COPD in stable state show normal serum levels of VIP and vitamin C before and after therapy.
CLINICAL IMPLICATIONS: Elevation of serum vitamin C and decreased of serum VIP is good prognostic parameter in COPD patient during exacerbation.
DISCLOSURE: Ljiljana Corkovic, None.